AstraZenca, G42 Healthcare to manufacture pharma products in Abu Dhabi

Building on the ongoing efforts of the Department of Health – Abu Dhabi (DoH) in spearheading Abu Dhabi's healthcare ecosystem, AstraZeneca and G42 Healthcare, an artificial intelligence (AI)-powered healthcare company, have signed a strategic partnership agreement to locally manufacture innovative drugs in Abu Dhabi.

The binding agreement focuses on collaboration in four key areas including localising innovative industries, research and development, innovation and sustainability at a global scale. The agreement cements the emirate's position as a hub for research and innovation in life sciences and is the latest in a series of longstanding partnerships with key players in the pharmaceutical industry.

The agreement is in line with the National Strategy for Industry and Advanced Technology and the Make it in the Emirates initiative, which was launched by the Ministry of Industry and Advanced Technology to enhance the UAE's business environment and position as an attractive destination for local and global industrial investors. It also supports the growth and competitiveness of national industries, innovation and adoption of advanced technologies, and the UAE's position as a global hub for future industries.

In the presence of Abdulla bin Mohammed Al Hamed, Chairman of DoH, Pascal Soriot, Executive Director and Chief Executive Officer at AstraZeneca, Dr Jamal Mohammed Al Kaabi, Undersecretary of DoH, Peng Xiao, Group Chief Executive Officer at G42, the partnership was confirmed through the signing of a binding agreement by Ashish Koshy, Chief Executive Officer of G42 Healthcare and Pelin Incesu, Area Vice President, Middle East and Africa at AstraZeneca.